PRTA
Prothena Corp Plc
NASDAQ · Biotechnology
$8.91
+0.56 (+6.71%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 135.30M | 154.33M | 161.59M | 162.70M | 132.11M |
| Net Income | -122,441,672 | -125,695,796 | -23,577,083 | -26,550,677 | -16,869,914 |
| EPS | — | — | — | — | — |
| Profit Margin | -90.5% | -86.0% | -14.6% | -16.3% | -12.8% |
| Rev Growth | -12.3% | -12.3% | +2.5% | +13.5% | +18.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 99.01M | 103.68M | 102.66M |
| Total Equity | — | — | 260.66M | 280.84M | 243.54M |
| D/E Ratio | — | — | 0.38 | 0.37 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -154,018,338 | -166,895,655 | -38,324,386 | -39,466,979 | -33,822,388 |
| Free Cash Flow | — | — | -23,372,794 | -19,760,246 | -19,201,664 |